Transforming Patient Care by Unlocking New Target Spaces
March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers
Focused on Excellence
Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity of additional gene editing.
Our team is dedicated to ensuring the underlying engine of our cell therapies achieves peak function by minimizing cell manipulations and focusing on cell quality during production.
We have developed a streamlined manufacturing process to ensure consistent and robust production of high-quality CAR T-cells.
We are dedicated to revolutionizing patient care by unlocking new targets for challenging indications. To meet this goal, we have developed a team of innovators and experienced cell therapy drug developers
MB-105 is a CD5 CAR T-cell therapy in clinical development for T-cell lymphoma:
10-20% Of Patients
with relapsed / refractory T-cell lymphoma will survive 3 years, depending on the subtype
Narrow therapeutic options
leave patients with reduced chances for positive outcomes
Limited Targeted drug development
due to challenges with on-target, off-tumor toxicity
News & Publications
Read more about the research and impacts of the March Biosciences pipeline.